Brainsway Ltd. obtained three FDA-cleared indications for its proprietary Deep TMS platform technology.
2 reports, 1 independent
Updated Jul 29
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Brainsway Ltd. obtained three FDA-cleared indications for its proprietary Deep TMS platform technology.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Brainsway Ltd.
Medical technology company
Nothing else this week.
- FDA
-
TMS
American metadata company
Related events
- Brainsway Ltd. and TriSalus Life Sciences are identified as small-cap healthcare companies.
- FDA and state authorities are investigating product manufacturers in Utah.
- SSM Health, located in Southern Illinois, is utilizing technology that has received clearance from the FDA.
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
Coverage
Newest first; wire copies grouped- GlobeNewswireBrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025 BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or th